Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaz Groen

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Journal of Traumatic Stress|August 6, 2011
Trauma and psychotic symptoms: data from a pediatric mental health inpatient unitCassandra Hainsworth, Jean Starling, Fernande Brand, et al.
International Journal of Medical Informatics|October 27, 2023
Correctly structured problem lists lead to better and faster clinical decision-making in electronic health records compared to non-curated problem lists: A single-blinded crossover randomized controlled trialEva S Klappe, Jarom Heijmans, Kaz Groen, et al.
Cancers|November 27, 2021
A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple MyelomaMaarten R Seefat, David G J Cucchi, Stijn Dirven, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 15, 2026
Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen-Directed CAR T-Cell TherapyMaria T Kuipers, Jorne Migchelbrink, Anne Marijn Kramer, et al.
Blood Cancer Journal|February 20, 2026
Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamabFebe Smits, Kaz Groen, Charlotte L B M Korst, et al.
Blood Cancer Journal|November 12, 2021
Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based studyMirian Brink, Kaz Groen, Pieter Sonneveld, et al.
Hemasphere|July 25, 2024
Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosingCharlotte L B M Korst, Kaz Groen, Patricia W C Bosman, et al.
Blood|August 19, 2025
A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapyWassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
American Journal of Hematology|March 16, 2026
Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B-Cell Non-Hodgkin LymphomaWouter Verhaar, Flores Weverling, Jahanzaib Khwaja, et al.
Blood Advances|December 5, 2023
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementationKristine A Frerichs, Christie P M Verkleij, Maria Victoria Mateos, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Journal of Traumatic Stress|August 6, 2011
Trauma and psychotic symptoms: data from a pediatric mental health inpatient unitCassandra Hainsworth, Jean Starling, Fernande Brand, et al.
International Journal of Medical Informatics|October 27, 2023
Correctly structured problem lists lead to better and faster clinical decision-making in electronic health records compared to non-curated problem lists: A single-blinded crossover randomized controlled trialEva S Klappe, Jarom Heijmans, Kaz Groen, et al.
Cancers|November 27, 2021
A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple MyelomaMaarten R Seefat, David G J Cucchi, Stijn Dirven, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 15, 2026
Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen-Directed CAR T-Cell TherapyMaria T Kuipers, Jorne Migchelbrink, Anne Marijn Kramer, et al.
Blood Cancer Journal|February 20, 2026
Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamabFebe Smits, Kaz Groen, Charlotte L B M Korst, et al.
Blood Cancer Journal|November 12, 2021
Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based studyMirian Brink, Kaz Groen, Pieter Sonneveld, et al.
Hemasphere|July 25, 2024
Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosingCharlotte L B M Korst, Kaz Groen, Patricia W C Bosman, et al.
Blood|August 19, 2025
A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapyWassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
American Journal of Hematology|March 16, 2026
Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B-Cell Non-Hodgkin LymphomaWouter Verhaar, Flores Weverling, Jahanzaib Khwaja, et al.
Blood Advances|December 5, 2023
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementationKristine A Frerichs, Christie P M Verkleij, Maria Victoria Mateos, et al.
Pageof 2